Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment

Suxia Geng, Ruohao Xu, Xin Huang, Minming Li, Chengxin Deng, Peilong Lai, Yulian Wang, Ping Wu, Xiaomei Chen, Jianyu Weng, Xin DuFrontiers in Immunology 2022 · DOI

TL;DR

This study investigates the dynamic expression of PD-1 and its ligands (PD-L1, PD-L2) in patients with higher-risk myelodysplastic syndromes (MDS) undergoing hypomethylating agent (HMA) treatment. They found that elevated PD-1 levels after just two cycles of HMA treatment are a strong predictor of disease progression to acute myeloid leukemia (AML) and poorer survival, suggesting a potential window for targeted immunotherapy.

What Problem Does This Paper Address?

Myelodysplastic syndromes (MDS) are a group of blood cancers characterized by bone marrow failure and a high risk of transforming into acute myeloid leukemia (AML). Hypomethylating agents (HMAs) are a standard treatment for higher-risk MDS, but their effectiveness is limited, with less than 50% of patients responding and many relapsing. Emerging research suggests that HMAs might upregulate immune checkpoint proteins, like PD-1, which can hinder the immune system's ability to fight cancer. While combining HMAs with PD-1 inhibitors shows promise, it's unclear which patients would benefit most or when to administer this combination therapy. This paper aims to fill this gap by examining how PD-1 and its ligands change during HMA treatment and whether these dynamics can predict treatment outcomes, specifically AML transformation and survival.

Methods

The researchers employed a multi-pronged approach:

  • Quantitative PCR (Q-PCR): This was the primary method to measure the mRNA expression levels of PD-1, PD-L1, and PD-L2 in bone marrow samples. They collected samples at multiple time points: before treatment (baseline), after the 2nd cycle (C2), 4th cycle (C4), and 6th cycle (C6) of HMA therapy.
  • Flow Cytometry: Used to validate the Q-PCR findings by measuring PD-1 protein expression on immune cells in a subset of patients.
  • Targeted Gene Sequencing: Performed to analyze the mutational landscape of common genes (e.g., TET2, TP53) in MDS patients at diagnosis, providing context for their disease.
  • Statistical Analysis: A suite of statistical tools, including binary logistic regression and Receiver Operating Characteristic (ROC) curve analysis, was used to identify predictive factors and assess the significance of their findings.

Datasets

The study utilized data from:

  • A retrospective cohort of 135 MDS patients: This formed the primary group for analyzing baseline and dynamic expression of immune checkpoints.
  • Two independent prospective cohorts (NCT01599325 and NCT01751867) with 33 patients: These cohorts served as validation groups to confirm the prognostic value of the observed dynamics.
  • A normal control group (n=23): Used for comparison to establish baseline immune checkpoint expression levels in healthy individuals.

Key Insights and Ideas

  • PD-1 is differentially expressed in MDS: Baseline PD-1 expression was significantly higher in MDS patients compared to healthy individuals. Interestingly, it was also higher in younger MDS patients and those with lower-risk stratification (intermediate-1) within the higher-risk MDS group.
  • HMAs dynamically alter PD-1 expression: A key finding is the significant upregulation of PD-1 expression after the first two cycles of HMA treatment. This effect was specific to PD-1, as PD-L1 and PD-L2 did not show similar dynamic changes.
  • PD-1 dynamics predict treatment failure: The study strongly suggests that elevated PD-1 levels after HMA treatment are not just a consequence but a predictor of negative outcomes.
  • A critical threshold for PD-1: The research identified a specific PD-1 expression level (≥75.9) after two HMA cycles as a significant independent predictor of AML transformation and reduced survival. This provides a concrete, actionable metric.

Key Results

  • Baseline PD-1 elevation: MDS patients showed significantly higher PD-1 expression compared to normal controls (58.77 ± 3.820 vs. 31.95 ± 3.692, P = 0.007).
  • HMA-induced PD-1 surge: PD-1 levels significantly increased after the first two cycles of HMA treatment (66.38 ± 7.709 vs. 42.74 ± 7.405, P = 0.03).
  • Prognostic value of post-HMA PD-1: An elevated PD-1 expression (≥75.9) after C2 was associated with a significantly higher risk of AML transformation (HR: 6.919; 95%CI: 1.213-39.47, P=0.03).
  • Survival impact: Patients with high PD-1 expression (≥75.9 at C2) had significantly shorter leukemia-free survival (LFS) (18.0 months vs. 27.0 months) and overall survival (OS) (20.0 months vs. 38.0 months) compared to those with lower PD-1 expression.

Limitations and Future Work

  • Retrospective nature: While validated in prospective cohorts, the initial analysis was retrospective, which can introduce biases.
  • Limited sample size for some analyses: Certain subgroup analyses, particularly for specific mutations or treatment responses, involved smaller numbers of patients.
  • Mechanism of PD-1 decrease: The study observed a decrease in PD-1 levels after the initial surge, but the underlying mechanism for this decline remains unclear and warrants further investigation.
  • Timing of immunotherapy: The findings strongly suggest that monitoring PD-1 dynamics could identify patients who would benefit from combined HMA and PD-1 inhibitor therapy. Future work should focus on prospective clinical trials to confirm this and determine the optimal timing for such interventions. This could lead to more personalized and effective treatment strategies for higher-risk MDS.

Summary updated

Abstract

Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidence indicates that demethylating effects committed by HMAs may facilitate the up-regulation of a range of immune checkpoints or cancer suppressor genes in patients with MDS, among which the programmed death protein 1 (PD-1) and its ligands are demonstrated to be prominent and may contribute to treatment failure and early relapse. Although results from preliminary studies with a limited number of enrolled patients indicate that combined administration of PD-1 inhibitor may yield extra therapeutic benefit in some MDS patients, identifications of this subgroup of patients and optimal timing for the anti-PD-1 intervention remain significant challenges. Dynamics of immune checkpoints and associated predictive values during HMA-treatment cycles remained poorly investigated. In this present study, expression levels of immune checkpoints PD-1 and its ligands PD-L1 and PD-L2 were retrospectively analyzed by quantitative PCR (Q-PCR) in a total of 135 myelodysplastic syndromes (MDS) cohort with higher-risk stratification. The prognostic value of dynamics of these immune checkpoints during HMA cycles was validated in two independent prospective cohorts in our center (NCT01599325 and NCT01751867). Our data revealed that PD-1 expression was significantly higher than that in younger MDS patients (age ≤ 60) and MDS with lower IPSS risk stratification (intermediate risk-1). A significantly up-regulated expression of PD-1 was seen during the first four HMA treatment cycles in MDS patients, while similar observation was not seen concerning the expression of PD-L1 or PD-L2. By utilizing binary logistic regression and receiver operating characteristic (ROC) models, we further identified that higher or equal to 75.9 PD-1 expressions after 2 cycles of HMA treatment is an independent negative prognostic factor in predicting acute myeloid leukemia (AML) transformation and survival. Collectively, our data provide rationales for monitoring the expression of PD-1 during HMA treatment cycles, a higher than 75.9 PD-1 expression may identify patients who will potentially benefit from the combined therapy of HMA and PD-1 inhibitors.
BibTeX
@inproceedings{geng2022dynamics,
  author = {Suxia Geng and Ruohao Xu and Xin Huang and Minming Li and Chengxin Deng and Peilong Lai and Yulian Wang and Ping Wu and Xiaomei Chen and Jianyu Weng and Xin Du},
  title = {{Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.950134},
}
Figure